Trial intelligence / Profile preview

Vildagliptin versus pioglitazone add-on to metformin in type 2 diabetes

2005-002199-14Phase 3Completed

Sponsor
Novartis
Start
Aug 2005
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Vildagliptin add-on to metformin with Pioglitazone add-on to metformin (2 arms). Primary endpoint: Change from baseline in HbA1c at Week 52. Started Aug 2005; status: completed.

02

Drugs

vildagliptinpioglitazone
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on 2005-002199-14.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-002199-14.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call